Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURACVE:GPHNYSEMKT:IGCNASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$5.84-4.1%$5.63$4.35▼$12.38$293.57M0.43206,578 shs266,431 shsGPHGraphite OneC$0.84+6.3%C$0.87C$0.55▼C$1.07C$85.05M1.0263,255 shs18,700 shsIGCIGC Pharma$0.32-2.8%$0.30$0.25▼$0.55$26.85M1.5335,844 shs214,616 shsKODKodiak Sciences$3.45-3.4%$3.31$1.92▼$11.60$182.04M2.42346,642 shs590,286 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences+1.50%+2.53%+9.53%-18.69%-18.91%GPHGraphite One-9.20%-3.66%-5.95%-19.39%-3.66%IGCIGC Pharma+0.61%-2.37%+10.77%+14.24%+32,899,900.00%KODKodiak Sciences+2.00%+0.56%-14.18%-13.14%+21.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAURAAura Biosciences2.6249 of 5 stars3.61.00.00.03.93.30.0GPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AIGCIGC Pharma1.6424 of 5 stars3.50.00.00.01.81.70.0KODKodiak Sciences4.1246 of 5 stars3.03.00.04.61.93.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 3.25Buy$22.00276.71% UpsideGPHGraphite One 0.00N/AN/AN/AIGCIGC Pharma 3.00Buy$3.881,122.40% UpsideKODKodiak Sciences 2.00Hold$9.00160.87% UpsideCurrent Analyst Ratings BreakdownLatest KOD, GPH, IGC, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$22.005/23/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.003/31/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.003/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.003/24/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/6/2025IGCIGC PharmaAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.50(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/AGPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AIGCIGC Pharma$1.24M20.44N/AN/A$0.08 per share3.96KODKodiak SciencesN/AN/AN/AN/A$5.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$76.41M-$1.90N/AN/AN/AN/A-41.57%-36.43%8/14/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AIGCIGC Pharma-$13M-$0.11N/AN/AN/A-714.16%-122.44%-88.40%N/AKODKodiak Sciences-$260.49M-$3.63N/AN/AN/AN/A-84.52%-45.40%8/13/2025 (Estimated)Latest KOD, GPH, IGC, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A3/27/2025Q4 2024KODKodiak Sciences-$0.90-$0.84+$0.06-$0.84N/AN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A12.4712.47GPHGraphite One0.021.090.33IGCIGC Pharma0.021.150.98KODKodiak SciencesN/A8.428.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%GPHGraphite One0.07%IGCIGC Pharma3.87%KODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences5.40%GPHGraphite One28.81%IGCIGC Pharma31.48%KODKodiak Sciences45.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5050.27 million47.25 millionNot OptionableGPHGraphite One20101.25 millionN/ANot OptionableIGCIGC Pharma6179.69 million54.60 millionN/AKODKodiak Sciences9052.76 million28.79 millionOptionableKOD, GPH, IGC, and AURA HeadlinesRecent News About These CompaniesKodiak Sciences to Present at 2025 Jefferies Global Healthcare ConferenceMay 29 at 9:32 PM | prnewswire.comKodiak Sciences’ SWOT analysis: eye disease biotech stock at crossroadsMay 29 at 3:23 PM | investing.comKodiak Sciences Q2 EPS Forecast Decreased by HC WainwrightMay 23, 2025 | marketbeat.comAnalysts Issue Forecasts for Kodiak Sciences Q2 EarningsMay 23, 2025 | americanbankingnews.comPoint72 Asset Management L.P. Buys New Shares in Kodiak Sciences Inc. (NASDAQ:KOD)May 22, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Reduces Position in Kodiak Sciences Inc. (NASDAQ:KOD)May 17, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Invests $902,000 in Kodiak Sciences Inc. (NASDAQ:KOD)May 17, 2025 | marketbeat.comKodiak Sciences (KOD) Projected to Post Earnings on WednesdayMay 16, 2025 | marketbeat.comKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deKodiak Sciences Shares Drop After Wider-Than-Expected 1Q LossMay 15, 2025 | marketwatch.comKodiak Q1 Loss Wider Than Expected, Pipeline Development in FocusMay 15, 2025 | zacks.comKodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comWhy Kodiak Sciences Inc.’s (KOD) Stock Is Down 15.35%May 7, 2025 | aaii.comBlackRock, Inc. Reduces Stake in Kodiak Sciences Inc.May 6, 2025 | gurufocus.comKodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Price T Rowe Associates Inc. MDMay 5, 2025 | marketbeat.comBoxer Capital Management LLC Invests $9.95 Million in Kodiak Sciences Inc. (NASDAQ:KOD)May 4, 2025 | marketbeat.comMore companies announce ARVO 2025 presentationsMay 2, 2025 | ophthalmologytimes.comKodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular DiseasesMay 1, 2025 | prnewswire.comTCG Crossover Management LLC Buys 137,380 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)May 1, 2025 | marketbeat.comNantahala Capital Management LLC Has $2.65 Million Stock Holdings in Kodiak Sciences Inc. (NASDAQ:KOD)April 30, 2025 | marketbeat.com1,139,527 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Purchased by Adage Capital Partners GP L.L.C.April 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, GPH, IGC, and AURA Company DescriptionsAura Biosciences NASDAQ:AURA$5.84 -0.25 (-4.11%) Closing price 04:00 PM EasternExtended Trading$6.20 +0.36 (+6.23%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Graphite One CVE:GPHC$0.84 +0.05 (+6.33%) As of 03:17 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.IGC Pharma NYSEMKT:IGC$0.32 -0.01 (-2.79%) Closing price 03:59 PM EasternExtended Trading$0.32 +0.00 (+1.26%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Kodiak Sciences NASDAQ:KOD$3.45 -0.12 (-3.36%) Closing price 04:00 PM EasternExtended Trading$3.40 -0.05 (-1.45%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
